Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 4
2007 6
2008 6
2009 3
2010 5
2011 1
2012 1
2013 5
2014 1
2015 1
2016 4
2017 7
2018 6
2019 4
2020 15
2021 11
2022 12
2023 15
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Medical nutrition therapy during intensive remission-induction treatment and hematopoietic stem cell transplantation in acute myeloid leukemia patients: Hematologists' experiences and perspectives.
van Lieshout R, Tick LW, de Beer F, Koene HR, Regelink JC, Westerweel PE, de Witte MA, Beckers EAM, Schouten HC, Beijer S. van Lieshout R, et al. Among authors: westerweel pe. Clin Nutr ESPEN. 2023 Oct;57:399-409. doi: 10.1016/j.clnesp.2023.07.015. Epub 2023 Jul 18. Clin Nutr ESPEN. 2023. PMID: 37739686
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL.
Hengeveld PJ, Kolijn PM, Demmers JAA, Doff W, Dubois JMN, Rijken M, Assmann JLJC, van der Straten L, Boiten HJ, Gussinklo KJ, Valk PJM, Faber LM, Westerweel PE, Kater AP, Levin MD, Langerak AW. Hengeveld PJ, et al. Among authors: westerweel pe. Hemasphere. 2023 Sep 15;7(10):e951. doi: 10.1097/HS9.0000000000000951. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37731707 Free PMC article.
Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial.
van Baarle FLF, van de Weerdt EK, van der Velden WJFM, Ruiterkamp RA, Tuinman PR, Ypma PF, van den Bergh WM, Demandt AMP, Kerver ED, Jansen AJG, Westerweel PE, Arbous MS, Determann RM, van Mook WNKA, Koeman M, Mäkelburg ABU, van Lienden KP, Vlaar APJ, Biemond BJ. van Baarle FLF, et al. Among authors: westerweel pe. Am J Hematol. 2023 Nov;98(11):E305-E308. doi: 10.1002/ajh.27053. Epub 2023 Aug 21. Am J Hematol. 2023. PMID: 37605361 No abstract available.
Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.
Hengeveld PJ, Veelken H, van Bergen CAM, Quinten E, Vervoordeldonk MYL, Ismailzada W, Barendse RS, Dubois JMN, van Oers MHJ, Geisler CH, Kater AP, Westerweel PE, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: westerweel pe. Leukemia. 2023 Sep;37(9):1929-1932. doi: 10.1038/s41375-023-01975-0. Epub 2023 Jul 21. Leukemia. 2023. PMID: 37479761 Free PMC article. No abstract available.
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.
Hengeveld PJ, Schilperoord-Vermeulen J, van der Klift MY, Dubois JMN, Kolijn PM, Kavelaars FG, Rijken M, Dobber JA, Nasserinejad K, Kersting S, Westerweel PE, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: westerweel pe. Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2. Blood Cancer J. 2023. PMID: 37400508 Free PMC article. No abstract available.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
van der Straten L, Stege CAM, Kersting S, Nasserinejad K, Dubois J, Dobber JA, Mellink CHM, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken JH, Levenga H, Tick LW, Terpstra WE, Tonino SH, Westerweel PE, Langerak AW, Kater AP, Levin MD. van der Straten L, et al. Among authors: westerweel pe. Blood. 2023 Sep 28;142(13):1131-1142. doi: 10.1182/blood.2023020195. Blood. 2023. PMID: 37363833
Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia.
van Baarle FLF, van de Weerdt EK, van der Velden WJFM, Ruiterkamp RA, Tuinman PR, Ypma PF, van den Bergh WM, Demandt AMP, Kerver ED, Jansen AJG, Westerweel PE, Arbous SM, Determann RM, van Mook WNKA, Koeman M, Mäkelburg ABU, van Lienden KP, Binnekade JM, Biemond BJ, Vlaar APJ. van Baarle FLF, et al. Among authors: westerweel pe. N Engl J Med. 2023 May 25;388(21):1956-1965. doi: 10.1056/NEJMoa2214322. N Engl J Med. 2023. PMID: 37224197 Clinical Trial.
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Geelen IGP, Gullaksen SE, Ilander MM, Olssen-Strömberg U, Mustjoki S, Richter J, Blijlevens NMA, Smit WM, Gjertsen BT, Gedde-Dahl T, Markevärn B, Koppes MMA, Westerweel PE, Hjorth-Hansen H, Janssen JJWM. Geelen IGP, et al. Among authors: westerweel pe. Ann Hematol. 2023 Jun;102(6):1395-1408. doi: 10.1007/s00277-023-05199-1. Epub 2023 Apr 29. Ann Hematol. 2023. PMID: 37119314 Clinical Trial.
98 results